rozanolixizumab gMG
Selected indexed studies
- Rozanolixizumab: First Approval. (Drugs, 2023) [PMID:37656420]
- Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions. (J Neuromuscul Dis, 2025) [PMID:40033991]
- Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. (Ther Adv Neurol Disord, 2024) [PMID:39297052]
_Worker-drafted node — pending editorial review._
Connections
rozanolixizumab gMG is a side effect of
Sources
- The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis. (2024) pubmed
- Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis. (2024) pubmed
- Rozanolixizumab: First Approval. (2023) pubmed
- Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions. (2025) pubmed
- Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. (2024) pubmed
- Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension. (2025) pubmed
- Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. (2025) pubmed
- Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. (2021) pubmed
- Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study. (2025) pubmed
- Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study. (2025) pubmed